New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:14 EDTCPRXCatalyst Pharmaceutical initiated with an Overweight at Piper Jaffray
Target $4.
News For CPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
08:22 EDTCPRXCatalyst Pharmaceutical appoints Dr. Gary Ingenito as Chief Medical Officer
Catalyst Pharmaceuticals announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
June 29, 2015
08:07 EDTCPRXCatalyst Pharmaceutical study results encouraging, says SunTrust
SunTrust believes that data from a study of Catalyst's CPP-109 in patients with Refractory Tourette's Disorder was encouraging. The firm thinks the results provide strong proof-of-concept for the use of GABA minotransferase inhibitors in Tourette's Disorder. SunTrust says that the drug could enable the company's results to beat expectations by a significant amount. It keeps a Buy rating on the shares.
June 24, 2015
10:00 EDTCPRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTCPRXCatalyst Pharmaceutical initiated with a Buy at MLV & Co.
Target $14.
09:10 EDTCPRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTCPRXCatalyst Pharmaceutical announces top-line results in vigabatrin trial
Catalyst Pharmaceuticals announced top-line results in an open-label, proof-of-concept trial of CPP-109, vigabatrin, used to treat patients suffering from Tourette's Disorder, or TD, that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement. This proof-of-concept trial of CPP-109 for Treatment-Refractory Tourette's Disorder was conducted by Barbara Coffey M.D., M.S., Co-Principal Investigator and Chief of the Tics and Tourette’s Clinical and Research Program at the Icahn School of Medicine at Mount Sinai in New York, in collaboration with Dr. Jonathan D. Brodie at the NYU Langone Medical Center, the Co-Principal Investigator and lead inventor of this use of GABA-AT inhibitors. The trial was designed to obtain preliminary data regarding clinical effect, dosage, and tolerability of vigabatrin in subjects at least 18 years of age with a DSM-IV-TR diagnosis of Tourette's Disorder, who exhibited unsatisfactory response to all prior treatments.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use